Floatz logo

Sargramostim

Intraocular Melanoma

Thomas Jefferson Universityprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

63 Active assets in the Intraocular Melanoma cohort.

Asset / SponsorPhaseRating
Ifa
Craig L Slingluff, Jr
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2/3BB
Darovasertib
IDEAYA Biosciences
Phase 3BB
Gm-Csf
Ahmad Tarhini
Phase 2BB

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →